^
Association details:
| Biomarker: | EGFR mutation + TSLP underexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
17P - The value of Th2-related thymic stromal lymphopoietin as a prognostic and predictive biomarker in non-small cell lung cancer
Published date:
03/17/2021
Excerpt:
101 advanced EGFR mutated lung adenocarcinoma patients were treated with TKIs until progression or unacceptable toxicity....Low TSLP expression predicted a favorable response to TKIs with a ROC cut-off value of 1.006 (AUC 0.713, 95% CI 0.569–0.831, p = 0.0015).
